A Curative Approach to Peritoneal Carcinomatosis from Colorectal Cancer
- 作者Paul H. Sugarbaker
- 卷第32卷
- 印刷ISSN0093-7754
- 文件大小232.57KB
- 发表时间2005
- DOI10.1053/j.seminoncol.2005.06.009
- 页码68-73
PCN22 COST-EFFECTIVENESS OF SUNITINIBAS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CANCER IN BELGIUMF Van Nooten; S Dewilde; S Van Belle; S Marbaix · 2007
Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapyBecker, J.; Lorenz, E.; Haas, G.; Helwig, C.; Oksen, D.; Mahnke, L.; Bharmal, M. · Annals of Oncology · 2016
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patientsLevy, Antonin; Menard, Jean; Albiges, Laurence; Loriot, Yohann; Di Palma, Mario; Fizazi, Karim; Escudier, Bernard · European Journal of Cancer · 2013
Budget Impact Analysis of Using Pazopanib-Everolimus in First and Second Line of Treatment, In Patients with Metastatic Renal Cell CarcinomaRomero Prada, ME; Celis, S; Acero, G; Huerfano, LM · Value in Health · 2016
Phase I study of an all-oral combination of vinorelbine (VRL) and cyclophosphamide (Ctx) as second line treatment in patients with metastatic breast cancer (MBC)2002
DOCETAXEL AND IFOSFAMIDE AS SECOND LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CANCER AFTER FAILURE OF PLATINUM CHEMOTHERAPY: A PHASE 2 STUDYKREGE, S.; REMBRINK, V.; BÖRGERMANN, C.H.; OTTO, T.; RÜBBEN, H. · The Journal of Urology · 2001
Frequency and Costs Associated with Targeted Therapy-Related Adverse Events (AES) During First and Second Line of Treatment (LOT) Among Patients with Metastatic Colorectal Cancer (MCRC)DaCosta Byfield, S.; Langer, C.; Ogale, S.; Morlock, R. · Value in Health · 2014
Phase I/II trial of oral UFT/Leucovorin (LV) and paclitaxel (P) in the second line treatment of patients (PTS) with metastatic breast cancer (MBC)Klaassen, U.; Lang, S.; Borquez, D.; Oberhoff, C.; Benner, S.; Harstrick, A.; Seeber, S. · European Journal of Cancer · 1999